Clinical Trial Update: A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis [Phase 3]

View source ↗

Summary

Phase 3 study comparing SB16, a proposed denosumab biosimilar, to Prolia in postmenopausal osteoporosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• Prolia (denosumab)
• SB16 (denosumab)

Snippet

Sponsor: Samsung Bioepis Co., Ltd. | Conditions: Postmenopausal Osteoporosis | Phase 3 | Status: COMPLETED | Results posted: 2025-01-09